MNKD
NASDAQ · Biotechnology
Mannkind Corp
$4.11
+0.22 (+5.66%)
Open$3.91
Previous Close$3.89
Day High$4.15
Day Low$3.85
52W High$6.51
52W Low$2.23
Volume—
Avg Volume5.81M
Market Cap1.25B
P/E Ratio—
EPS$-0.08
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+669.1% upside
Current
$4.11
$4.11
Target
$31.61
$31.61
$20.51
$31.61 avg
$34.61
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 354.60M | 233.63M | 248.98M |
| Net Income | 5.97M | 3.54M | -49,454,944 |
| Profit Margin | 1.7% | 1.6% | -19.9% |
| EBITDA | 43.47M | 27.21M | -82,218,351 |
| Free Cash Flow | — | — | -29,596,680 |
| Rev Growth | +51.8% | +51.8% | +22.2% |
| Debt/Equity | 1.64 | 1.64 | 1.00 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |